Trader consensus on Polymarket prices "No" at 82.5% for a new COVID-19 variant of concern before 2027, driven by the absence of any WHO or ECDC-designated VOCs as of May 2026 despite ongoing SARS-CoV-2 evolution. The recent BA.3.2 ("Cicada") Omicron sublineage, first detected in late 2024 and hyped for spreading in 25 U.S. states and Europe via wastewater surveillance since March, exhibits immune escape with 70+ spike mutations but shows no increased severity, transmissibility, or dominance—key VOC criteria—per latest assessments up to April 24. Hybrid immunity from vaccines and infections, plus low hospitalization rates in a post-wave lull, underpins this positioning, though genomic monitoring continues ahead of WHO's May antigen deliberations.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоДа
$238,509 Объем
$238,509 Объем
Да
$238,509 Объем
$238,509 Объем
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Открытие рынка: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus on Polymarket prices "No" at 82.5% for a new COVID-19 variant of concern before 2027, driven by the absence of any WHO or ECDC-designated VOCs as of May 2026 despite ongoing SARS-CoV-2 evolution. The recent BA.3.2 ("Cicada") Omicron sublineage, first detected in late 2024 and hyped for spreading in 25 U.S. states and Europe via wastewater surveillance since March, exhibits immune escape with 70+ spike mutations but shows no increased severity, transmissibility, or dominance—key VOC criteria—per latest assessments up to April 24. Hybrid immunity from vaccines and infections, plus low hospitalization rates in a post-wave lull, underpins this positioning, though genomic monitoring continues ahead of WHO's May antigen deliberations.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы